Prophylactic cranial irradiation in small cell lung cancer: Rationale, results, and recommendations

Michael Glantz, H. Choy, L. Yee

Research output: Contribution to journalReview article

42 Citations (Scopus)

Abstract

The utility of prophylactic cranial irradiation (PCI) in patients with small cell lung cancer (SCLC) constitutes one of the longest running debates in ontology. Despite dozens of prospective and retrospective studies and decades of individual experience, a consensus has been reached on only two issues: (1) when administered to all patients with SCLC, PCI decreases the likelihood of developing brain metastases by about half, but (2) PCI does not significantly prolong survival. Uncertainty persists over many critical questions, including whether, when, and how to administer PCI; whether identifiable subgroups of patients benefit more tangibly from PCI; how frequent and severe the long-term side effects of PCI are; whether withholding treatment until brain metastases are diagnosed is clinically responsible and cost effective; and how newer forms of treatment for brain metastases should be integrated into the picture. In this review, we discuss the epidemiology and natural history of brain metastases in patients with SCLC, the results of studies examining the efficacy of PCI, data on the early and late toxicities of PCI, and the status of alternative therapies for patients with brain metastases from SCLC. Based on this information, an approach to newly diagnosed patients is suggested, and recommendations for future study are made.

Original languageEnglish (US)
Pages (from-to)477-483
Number of pages7
JournalSeminars in oncology
Volume24
Issue number4
StatePublished - Sep 4 1997

Fingerprint

Cranial Irradiation
Small Cell Lung Carcinoma
Neoplasm Metastasis
Brain
Withholding Treatment
Complementary Therapies
Natural History
Uncertainty
Epidemiology
Retrospective Studies
Prospective Studies
Costs and Cost Analysis
Survival

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

Cite this

@article{5059ad19100047659e34e3d6db230fed,
title = "Prophylactic cranial irradiation in small cell lung cancer: Rationale, results, and recommendations",
abstract = "The utility of prophylactic cranial irradiation (PCI) in patients with small cell lung cancer (SCLC) constitutes one of the longest running debates in ontology. Despite dozens of prospective and retrospective studies and decades of individual experience, a consensus has been reached on only two issues: (1) when administered to all patients with SCLC, PCI decreases the likelihood of developing brain metastases by about half, but (2) PCI does not significantly prolong survival. Uncertainty persists over many critical questions, including whether, when, and how to administer PCI; whether identifiable subgroups of patients benefit more tangibly from PCI; how frequent and severe the long-term side effects of PCI are; whether withholding treatment until brain metastases are diagnosed is clinically responsible and cost effective; and how newer forms of treatment for brain metastases should be integrated into the picture. In this review, we discuss the epidemiology and natural history of brain metastases in patients with SCLC, the results of studies examining the efficacy of PCI, data on the early and late toxicities of PCI, and the status of alternative therapies for patients with brain metastases from SCLC. Based on this information, an approach to newly diagnosed patients is suggested, and recommendations for future study are made.",
author = "Michael Glantz and H. Choy and L. Yee",
year = "1997",
month = "9",
day = "4",
language = "English (US)",
volume = "24",
pages = "477--483",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "4",

}

Prophylactic cranial irradiation in small cell lung cancer : Rationale, results, and recommendations. / Glantz, Michael; Choy, H.; Yee, L.

In: Seminars in oncology, Vol. 24, No. 4, 04.09.1997, p. 477-483.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Prophylactic cranial irradiation in small cell lung cancer

T2 - Rationale, results, and recommendations

AU - Glantz, Michael

AU - Choy, H.

AU - Yee, L.

PY - 1997/9/4

Y1 - 1997/9/4

N2 - The utility of prophylactic cranial irradiation (PCI) in patients with small cell lung cancer (SCLC) constitutes one of the longest running debates in ontology. Despite dozens of prospective and retrospective studies and decades of individual experience, a consensus has been reached on only two issues: (1) when administered to all patients with SCLC, PCI decreases the likelihood of developing brain metastases by about half, but (2) PCI does not significantly prolong survival. Uncertainty persists over many critical questions, including whether, when, and how to administer PCI; whether identifiable subgroups of patients benefit more tangibly from PCI; how frequent and severe the long-term side effects of PCI are; whether withholding treatment until brain metastases are diagnosed is clinically responsible and cost effective; and how newer forms of treatment for brain metastases should be integrated into the picture. In this review, we discuss the epidemiology and natural history of brain metastases in patients with SCLC, the results of studies examining the efficacy of PCI, data on the early and late toxicities of PCI, and the status of alternative therapies for patients with brain metastases from SCLC. Based on this information, an approach to newly diagnosed patients is suggested, and recommendations for future study are made.

AB - The utility of prophylactic cranial irradiation (PCI) in patients with small cell lung cancer (SCLC) constitutes one of the longest running debates in ontology. Despite dozens of prospective and retrospective studies and decades of individual experience, a consensus has been reached on only two issues: (1) when administered to all patients with SCLC, PCI decreases the likelihood of developing brain metastases by about half, but (2) PCI does not significantly prolong survival. Uncertainty persists over many critical questions, including whether, when, and how to administer PCI; whether identifiable subgroups of patients benefit more tangibly from PCI; how frequent and severe the long-term side effects of PCI are; whether withholding treatment until brain metastases are diagnosed is clinically responsible and cost effective; and how newer forms of treatment for brain metastases should be integrated into the picture. In this review, we discuss the epidemiology and natural history of brain metastases in patients with SCLC, the results of studies examining the efficacy of PCI, data on the early and late toxicities of PCI, and the status of alternative therapies for patients with brain metastases from SCLC. Based on this information, an approach to newly diagnosed patients is suggested, and recommendations for future study are made.

UR - http://www.scopus.com/inward/record.url?scp=0030825255&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030825255&partnerID=8YFLogxK

M3 - Review article

C2 - 9280227

AN - SCOPUS:0030825255

VL - 24

SP - 477

EP - 483

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 4

ER -